Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2022  |  Volume : 18  |  Issue : 2  |  Page : 516-524

Clinical data from the real world: Efficacy analysis of ceritinib (450mg) in ALK-rearrangement non-small-cell lung cancer patients with brain metastases in China


1 Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Sichuan Province, Chengdu, P.R. China
2 West China Clinical Medical College, Sichuan University, Sichuan Province, Chengdu, P.R. China
3 Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Sichuan Province, Chengdu, P.R. China
4 Department of Chest Oncology, West China Hospital, Sichuan University, Sichuan Province, Chengdu, P.R. China
5 Department of Thoracic Surgery, West China Hospital, Sichuan University, Sichuan Province, Chengdu, P.R. China
6 Department of Respiratory and Critical Care Medicine; Lung Cancer Treatment Center, West China Hospital, Sichuan University, Sichuan Province, Chengdu, P.R. China

Correspondence Address:
Ke Wang
Department of Respiratory and Critical Care Medicine, Lung Cancer Treatment Center, West China Hospital, Sichuan University, Sichuan Province, Chengdu, 610041
P.R. China
Meijuan Huang
Department of Chest Oncology, West China Hospital, Sichuan University, Sichuan Province, Chengdu
P.R. China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jcrt.jcrt_1453_21

Rights and Permissions

Objectives: The real-world intracranial efficacy data of ceritinib at a dose of 450 mg quaque die (QD) are currently unavailable. Therefore, we evaluated the intracranial efficacy of ceritinib (450 mg QD) in anaplastic lymphoma kinase (ALK)-rearrangement NSCLC patients in China. Materials and Methods: In total, 57 ALK-rearrangement NSCLC patients with brain metastases (BM) were enrolled retrospectively in this real-world study. Of these, 53 patients experienced progression at baseline during or after prior crizotinib administration, and 24 patients received prior brain radiotherapy. Patients received ceritinib (450 mg QD) treatment. Intracranial efficacy [objective response rate (ORR) and disease control rate (DCR)] was evaluated according to the Response Assessment in Neuro-Oncology (RANO) standard; progression-free survival (PFS) and adverse events (AEs) data were obtained through follow-ups. Results: The intracranial ORR and DCR of ceritinib were 73.7% and 93.0%, respectively. The median intracranial PFS in patients reaching the endpoint was 8.75 months, whereas the median intracranial PFS in all patients was not reached and predicted to be not evaluable (NE) (95% CI: 12.9–NE). The estimated 12-month event-free probability (EFP) of intracranial lesions was 68.1%. A subgroup analysis revealed that the estimated 12-month EFP of intracranial lesions was relatively higher in patients with prior brain radiotherapy (93.8% vs. 47.1%, P = 0.0006). Conclusion: Ceritinib administered at 450 mg QD to ALK-rearrangement NSCLC patients with BM in China exhibited superior ORR and DCR, as well as PFS and event free probability. The estimated 12-month EFP for intracranial lesions improved in patients with prior brain radiotherapy.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed182    
    Printed6    
    Emailed0    
    PDF Downloaded27    
    Comments [Add]    

Recommend this journal